Selskabets formål er forskning, udvikling og kommercialisering af lægemidler.
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | -5.5 mio. | -7 mio. | 5.5 mio. | -18.4 mio. | 5 | |
CVR: 41696451
Francesco Paolo Di Giorgio joined the board
Thomas Michael Thestrup left the board
Ellen Kinson Donnelly joined the board
Ellen Kinson Donnelly joined as ADM. DIR.
Janine Terra Erler left as ADM. DIR.
registered with 10% ownership
registered with 15% ownership
EY Godkendt Revisionspartnerselskab appointed as auditor
Beierholm Godkendt Revisionspartnerselskab resigned as auditor
HELLERUNG ApS registered with 25% ownership
Companies in the same industry and area
CVR 19352102
CVR 44931885
CVR 44214032
CVR 37065226
CVR 39525011
Compared to 992 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
companydata.dk